{"id":1131,"date":"2020-08-26T14:37:11","date_gmt":"2020-08-26T14:37:11","guid":{"rendered":"https:\/\/interhospi.3wstaging.nl\/guidelines-for-medication-management-in-patients-with-rheumatic-diseases-undergoing-hip-or-knee-replacement-surgery\/"},"modified":"2020-08-26T14:37:22","modified_gmt":"2020-08-26T14:37:22","slug":"guidelines-for-medication-management-in-patients-with-rheumatic-diseases-undergoing-hip-or-knee-replacement-surgery","status":"publish","type":"post","link":"https:\/\/interhospi.com\/guidelines-for-medication-management-in-patients-with-rheumatic-diseases-undergoing-hip-or-knee-replacement-surgery\/","title":{"rendered":"Guidelines for medication management in patients with rheumatic diseases undergoing hip or knee replacement surgery"},"content":{"rendered":"

In the first such collaboration of its kind, an expert panel of rheumatologists and orthopaedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.<\/span>
\n"Patients with rheumatic diseases who have joint replacement surgery are at increased risk for joint infection, a potentially devastating complication," said Susan Goodman, MD, co-principal investigator and a rheumatologist at Hospital for Special Surgery in New York City. "As infection risk is linked to the use of anti-rheumatic medication, our goal was to develop recommendations on when to stop medication prior to joint replacement and the optimal time for patients to restart treatment after surgery. Appropriate medication management in the perioperative period may provide an important opportunity to lower the risk of an infection or other adverse outcome."<\/span>
\nThe expert panel consisted of 31 specialists from more than 20 hospitals and professional organizations. The medication guidelines concern adults with rheumatoid arthritis; spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis; juvenile idiopathic arthritis; and lupus undergoing hip or knee replacement.<\/span>
\nThe study included traditional disease-modifying anti-rheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids. The panel developed guidelines on when to continue, when to withhold, and when to restart these medications, as well as the optimal perioperative dosing of corticosteroids.<\/span>
\nAmong the main recommendations:<\/span><\/p>\n